DARMSTADT, Germany - Thursday, 30. April 2026
Significant unmet need remains for 85% of lupus patients whose disease includes skin manifestations, often associated with substantial physical and psychosocial burden
Enpatoran, an oral TLR7/8 inhibitor, is designed for lupus patients with active cutaneous manifestations, with the goal of broadening the treatment paradigm beyond the current standards
ELOWEN is a global Phase 3 program evaluating enpatoran’s impact on both skin and systemic symptoms in patients with lupus and potential links between skin and systemic disease activity
(BUSINESS WIRE)--Merck, a leading global science and technology company, today announced the first patient was dosed in the Phase 3 program, ELOWEN-1 (NCT07332481) and ELOWEN-2 (NCT07355218), evaluating enpatoran in people living with lupus who experience active skin manifestations.
“People living with lupus continue to face significant challenges in achieving disease control and are very often affected by itchy, painful and stigmatized skin manifestations,” said David Weinreich, Global Head of R&D, Merck. “With enpatoran, we aim to target the underlying drivers of lupus and redefine how to approach the disease by understanding both visible skin manifestations and systemic activity.”
Enpatoran is an oral selective toll-like receptor (TLR) 7/8 inhibitor designed to modulate pathways central to lupus-related inflammation.1 By targeting these upstream drivers, enpatoran has the potential to impact disease activity and address a key aspect of the lupus mechanism that remains difficult to manage with current treatment approaches, while preserving the body’s broader immune function.1
“The ELOWEN program builds on Phase 2 findings, where enpatoran demonstrated clinically meaningful improvements in patients with active cutaneous manifestations, regardless of their underlying lupus diagnosis,” said Professor Eric Morand, principal investigator. “These studies are designed to further explore how targeting shared inflammatory pathways may benefit patients across the lupus spectrum.”
Lupus is a chronic autoimmune disease that can affect multiple organ systems, including the skin, joints, kidneys and central nervous system.2 Up to 85% of patients experience skin manifestations, which are among the most visible signs of disease and may reflect underlying immune-driven inflammation.1
Skin manifestations can be life-altering and sometimes are irreversible on their own.3,4 They can present as inflamed, photosensitive lesions on the face, scalp and other areas, and may lead to scarring or pigment changes.5 Despite their prevalence and the fact that skin manifestations are the first sign of disease in nearly one third (29%) of cases,1 many patients still do not achieve adequate disease control.6
“Skin symptoms impose a profound and multilayered burden that lingers long after flares subside. The lesions are visible, disfiguring and often painful, and the psychological weight can be equally debilitating, breeding a loss of identity that standard clinical assessments often fail to capture,” said Dr. Joy Buie, PhD, VP of Research at the Lupus Foundation of America. “These consequences erode participation in work, social life, and intimate relationships as self-consciousness and deliberate avoidance quietly reshape how patients navigate the world around them. It is vital we recognize skin manifestations as a visible and clinically actionable signal of underlying systemic disease "
ELOWEN-1 and ELOWEN-2 are two global randomized, double-blind, placebo-controlled Phase 3 studies evaluating enpatoran taken twice daily versus placebo, on top of standard of care, in patients with lupus who have active cutaneous manifestations. The ELOWEN studies will be conducted in 266 sites in 26 countries. Each study will recruit approximately 200 lupus participants, and the primary endpoint will be a change in CLASI-A from baseline.
About Enpatoran
Enpatoran is an investigational, oral, selective inhibitor of toll-like receptors 7 and 8 (TLR7/8), which play a key role in immune pathways involved in lupus. Enpatoran has the potential to be the first targeted therapy for lupus patients with active cutaneous manifestations, with the goal of broadening the treatment paradigm beyond the current standards of care for patients with CLE and SLE.
Enpatoran is currently under clinical investigation and has not been approved for any use anywhere in the world.
About the Phase 3 ELOWEN Program
ELOWEN-1 (NCT07332481) and ELOWEN-2 (NCT07355218) are two global randomized, double-blind, placebo-controlled Phase 3 studies evaluating enpatoran taken twice daily versus placebo, on top of standard of care, in patients with lupus who have active cutaneous manifestations. The ELOWEN studies will be conducted in 266 sites in 26 countries. Each study will recruit approximately 200 lupus participants, and the primary endpoint will be a change in CLASI-A from baseline.
About Lupus Erythematosus
Lupus erythematosus is a chronic autoimmune disease characterized by inflammation that can affect multiple organs and systems in the body. The disease is heterogeneous, with symptoms ranging from mild to life-threatening, and often follows a relapsing-remitting course.
Cutaneous manifestations are common (72-85%) of patients and can occur alongside or independently of systemic involvement. Beyond their physical presentation, they are associated with increased disease burden, including scarring, psychological impact and reduced quality of life.
Lupus disproportionately affects women and people of color, and many patients continue to experience unmet medical needs due to insufficient disease control or treatment-related side effects.
Merck in Neurology and Immunology
Merck has a long-standing legacy in neurology and immunology. The company’s current neurology portfolio includes two products for the treatment of relapsing MS – Rebif® (interferon beta-1a) and MAVENCLAD® (cladribine) tablets. Merck aims to improve the lives of patients by addressing areas of unmet medical needs. In addition to Merck’s commitment to MS, the company also has a pipeline focusing on discovering new therapies that have potential in other neuroinflammatory and immune-mediated diseases, including lupus and generalized myasthenia gravis (gMG).
About Merck
Merck, a leading science and technology company, operates across life science, healthcare and electronics. More than 62,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2025, Merck generated sales of € 21.1 billion in 65 countries.
Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as MilliporeSigma in life science, EMD Serono in healthcare, and EMD Electronics in electronics.
All Merck press releases are distributed by e-mail at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.
1 Childs B and Merola JF. From the Masterclasses in Dermatology 2025 Meeting: Practical Approaches to Cutaneous and Systemic Lupus for Dermatologists. J Clin Aesthet Dermatol. 2025;18(10):40–47.
2 Lupus Research Alliance. What Is Lupus? Available at: https://www.lupusresearch.org/about-lupus/what-is-lupus/. Last accessed: April 2026.
3 Klein R, Moghadam-Kia S, Taylor L, et al. Quality of Life in Cutaneous Lupus Erythematosus. J Am Acad Dermatol. 2011 Mar 12;64(5):849–858.
4 Chambers S, On A, Yang X, et al. Dyspigmentation and scarring in cutaneous lupus erythematosus. Lupus Sci Med. 2025;12(2).
5 Lupus Foundation of America. What is lupus? Available at: https://www.lupus.org/resources/what-is-lupus. Last accessed: April 2026.
6 Kandane-Rathnayake, Louthrenoo W, Hoi A, et al. ‘Not at target’: prevalence and consequences of inadequate disease control in systemic lupus erythematosus—a multinational observational cohort study. Arthritis Res Ther. 2022;24:70.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260430733656/en/
Permalink
https://www.aetoswire.com/en/news/54525685
Contacts
Media Relations
flavia.felix@emdserono.com
Phone: +1 781 427 1892
Saturday, May 2, 2026
Friday, May 1, 2026
Estithmar Holding : bond spectaculaire de 97 % du bénéfice net au T1 2026, à 333 millions de riyals qataris
Estithmar Holding Q.P.S.C. a annoncé ses résultats financiers pour le premier trimestre 2026, faisant état d’un bénéfice net de 333 millions de riyals qataris, soit une augmentation significative de 97 % par rapport à la même période de l’année précédente. Ces résultats soulignent la solidité du modèle opérationnel de la société, ainsi que l’exécution réussie de sa stratégie d’expansion.
La société a enregistré des revenus de 1,455 milliard de riyals qataris, contre 1,309 milliard de riyals qataris au premier trimestre 2025. Le bénéfice brut a atteint 561 millions de riyals qataris, contre 416 millions de riyals qataris, soit une progression annuelle de 35 %. L’EBITDA a augmenté de 73 % pour atteindre 473 millions de riyals qataris, tandis que le bénéfice par action a progressé de 90 % pour s’établir à 0,089 riyals qataris.
Ces résultats reflètent une croissance globale à travers l’ensemble des principaux indicateurs financiers, soutenue par une vision d’investissement claire et la capacité de Estithmar Holding Q.P.S.C. à concilier expansion géographique, diversification du portefeuille et efficacité opérationnelle. Les investissements internationaux annoncés au cours des périodes précédentes ont commencé à produire un impact tangible, contribuant à la croissance des revenus, à l’amélioration de la rentabilité et à l’expansion de la base d’actifs.
La forte croissance du bénéfice net est attribuée à l’approche rigoureuse de la Société en matière d’efficacité opérationnelle et de création de valeur, ainsi qu’à une gestion prudente du capital et à des pratiques efficaces de gestion des risques. Parallèlement, les initiatives de transformation numérique, notamment dans les domaines de l’automatisation et de l’intelligence artificielle, ont joué un rôle clé dans l’amélioration de la productivité, le renforcement de la gouvernance et l’optimisation des coûts.
Les résultats mettent également en évidence la contribution équilibrée des différents pôles d’activité de la Société — santé, services, tourisme et développement immobilier, ainsi qu’industries et contracting spécialisé — illustrant la réussite de chaque pôle dans la mise en œuvre de sa propre stratégie de croissance au sein d’un cadre stratégique intégré.
Commentant ces résultats, Juan Leon, PDG de Estithmar Holding Q.P.S.C., a déclaré :
« Les résultats du premier trimestre illustrent la solidité de notre modèle d’affaires et notre capacité à générer simultanément une croissance à la fois accélérée et durable. Plus que de simples résultats record, cette performance témoigne de la qualité de nos décisions d’investissement et de l’exécution rigoureuse de notre stratégie à travers les marchés et les secteurs. L’équilibre entre la croissance des revenus et l’amélioration de la rentabilité, soutenu par de solides performances opérationnelles et des flux de trésorerie sains, met en évidence notre efficacité, ainsi que notre capacité à transformer l’expansion en valeur tangible et durable pour les actionnaires ».
Pour en savoir plus, consultez le communiqué de presse dans son intégralité.
La seule version du communiqué qui fasse foi est celle du communiqué dans sa langue d’origine. La traduction devra toujours être confrontée au texte source, qui fera jurisprudence.
Contacts
Nesrine Nacef
Experian Announces Agent Trust to Power Trusted AI Driven Commerce
First-of-its-kind human-to-agent binding service for secure AI-driven commerce, developed with a growing ecosystem of agentic commerce collaborators, including Visa, Cloudflare and Skyfire
(BUSINESS WIRE) -- Experian today announced Experian Agent Trust™, a first-of-its-kind framework that establishes a secure, verifiable link between consumers and AI agents, bringing identity, and accountability to AI-driven transactions.
As AI agents begin to search and transact autonomously, they introduce a fundamental challenge for businesses: how to trust an action when it is no longer driven by a human. Without a verified connection between humans and AI agents, autonomous commerce introduces new risks in fraud, misrepresentation, and unauthorized transactions.
Experian Agent Trust addresses this challenge through a new “Know Your Agent” (KYA) framework, extending identity verification into the age of AI. The framework ensures that agent-initiated transactions are grounded in verified consumer identity.
“Agentic commerce will not scale without trust,” said Kathleen Peters, Chief Innovation Officer at Experian. “What’s required is verifying the agent, the human behind it, and their intent to purchase. This is a natural extension of Experian’s verification role in the ecosystem. We already help define trust in financial transactions; now we’re bringing that same leadership to agentic commerce.”
Experian Agent Trust is being developed within a growing ecosystem of collaborative agentic commerce contributors, including Visa, Cloudflare, and Skyfire, who are leading the development of secure and scalable AI-driven commerce across payments, networks, and digital interactions.
Trust Stack for Agentic Commerce
Within this ecosystem, Experian’s identity capabilities is designed to complement Visa Intelligent Commerce and Trusted Agent Protocol to support a layered framework for trust and secure agentic payments.
Experian Human to Agent Binding connects verified consumers, devices and AI agents, issuing a real time trust token that validates identity, and transaction risk.
Trusted Agent Protocol allows merchants to identify and verify AI agents through Visa’s trusted network to help confirm an agent’s legitimacy and authorization to act on behalf of a consumer.
Cloudflare enforces this trust layer at the network edge, where it already powers and protects approximately 20% of the world's internet traffic, and operates the next-generation AI stack to build, secure, and scale agents.
Visa Intelligent Commerce enables secure AI commerce transactions, using network tokenization.
Skyfire offers an open, standardized way to package and exchange agent-related information across platforms, enabling interoperability and complementing existing identity and payment systems.
“Visa has spent decades earning trust across global commerce, which matters even more as AI becomes part of how transactions happen,” said Rubail Birwadker, SVP, Head of Growth Products and Partnerships at Visa. “As the ecosystem evolves and approaches like Experian’s human-to-agent identity binding capabilities emerge, Visa Intelligent Commerce and Trusted Agent Protocol are designed to provide the secure foundation for agentic commerce experiences at global scale.”
"The rise of AI agents represents one of the most significant shifts in the history of digital commerce, but it can only succeed if the underlying infrastructure is rooted in trust,” said Stephanie Cohen, Chief Strategy Officer at Cloudflare. “Cloudflare is the best place to build and secure agents. By combining our network footprint with Experian's identity expertise, we're giving any business the tools to participate in agentic commerce with confidence."
“Agentic commerce only works if merchants can confidently understand who they are transacting with, and if agents can pay as reliably as people do,” said Amir Sarhangi, CEO and co-founder of Skyfire. “Through our collaboration with Experian’s Agent Trust ecosystem and our work on the Know Your Agent (KYAPay) protocol, we’re helping enable a seamless, interoperable trust layer that brings together identity and payments to unlock the full potential of autonomous transactions.”
A consumer might ask their AI agent to find the best noise-cancelling headset for an upcoming trip. The agent can evaluate products based on the consumer’s preferences and make a recommendation, for example a Bose headphone, and prepare the transaction for approval. Once the consumer authorizes the purchase, Human to Agent Binding helps confirm that the agent is acting on behalf of a verified individual.
Experian Agent Trust is designed to work with existing payment systems and frameworks, like Trusted Agent Protocol. At the center of the framework is Human-to-Agent Binding, which creates a secure, persistent link between verified individuals, their devices, and the AI agents. This enables a continuous, auditable history between who the user is, and how the agent behaves over time.
Experian issues an Agent Trust Token that validates identity, and transaction fraud risk in real-time. Together with the Experian Agent Registry, the system maintains dynamic trust scoring for AI agents based on behavior and other risk signals.
Built for an Open Ecosystem
Experian Agent Trust services are platform-agnostic and built to scale with the evolving agent ecosystem. By establishing a trusted connection between humans and AI agents, Experian is helping define the foundation for secure, scalable agentic commerce. These capabilities extend Experian’s leadership in identity verification and fraud prevention, where its solutions help clients avoid an estimated $15–19 billion in fraud losses annually.
To learn more, visit Experian’s blog: https://www.experian.com/blogs/news/2026/04/30/experian-agent-trust/
About Experian
Experian is a global data and technology company, powering opportunities for people and businesses around the world. We help to redefine lending practices, uncover and prevent fraud, simplify healthcare, deliver digital marketing solutions, and gain deeper insights into the automotive market, all using our unique combination of data, analytics and software. We also assist millions of people to realize their financial goals and help them to save time and money.
We operate across a range of markets, from financial services to healthcare, automotive, agrifinance, insurance, and many more industry segments.
We invest in talented people and new advanced technologies to unlock the power of data and to innovate. A FTSE 100 Index company listed on the London Stock Exchange (EXPN), we have a team of 25,200 people across 33 countries. Our corporate headquarters are in Dublin, Ireland. Learn more at experianplc.com.
Experian and the Experian marks used herein are trademarks or registered trademarks of Experian and its affiliates. Other product and company names mentioned herein are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260430719198/en/
Permalink
https://www.aetoswire.com/en/news/3004202654685
Contacts
Michael Troncale
Experian Public Relations
+1 714 830 5462
michael.troncale@experian.com
Annie Russell
Experian Public Relations
+1 949 683 5243
annie.russell@experian.com
CorFlow Therapeutics Announces Successful Completion of Phase 1 and First Patients Enrolled in Phase 2 of the MOCA II Pivotal Trial, Approval to Start the REVITALISE RCT in Europe, and Strengthening of Clinical Leadership
BAAR, Switzerland -
Milestones advance clinical progress and path to commercialization
(BUSINESS WIRE) -- CorFlow Therapeutics AG (CorFlow), a clinical-stage company focused on transforming the diagnosis and treatment for heart attack patients, today announced multiple milestones in advancing its clinical program and the strengthening of clinical leadership.
Phase 1 of the company’s MOCA II FDA Pivotal Trial was successfully reached after safety and performance goals were met with STEMI heart attack patients who had the proprietary PCoFI diagnostic measurement of microvascular obstruction (MVO) made during a stenting procedure, when compared to the reference standard diagnosis by cardiac MRI in the subsequent days. Phase 1 included 19 patients enrolled across 5 US and 3 European sites. MOCA II follows the FIH MOCA I study and primarily aims to validate the threshold value of the proprietary PCoFI measurement for diagnosing MVO in the setting of primary angioplasty compared to cardiac MRI. This milestone achievement, which was confirmed by the study’s independent DSMB (Data and Safety Monitoring Board) triggered the possibility for Phase 2 to begin in a larger wave of clinical trial sites in both the US and Europe.
The first patients in the MOCA II Phase II study were enrolled by Professor Marco Valgimigli at Cardiocentro Ticino Institute in Lugano, Switzerland. “I am excited to see the next generation of the CorFlow technology and advancement of the clinical program where the international pivotal study is now underway, for which the interventional cardiology community will eagerly await the results. Once the technology is readily available, it can help drive decision-making in the cath lab to improve our management of STEMI patients. Fast, accurate diagnosis of MVO is the key step we need to build from.”
CorFlow also announced that its parallel flagship clinical trial is now approved and can start enrolling patients. The novel randomized REVITALISE trial is now set to begin enrolment across UK, with France, Netherlands, and Spain following in the coming weeks. REVITALISE is intended to prospectively test the effectiveness of the proprietary CorFlow Continuous Flow Infusion System (CoFI System) to deliver therapeutic agents in treating MVO in patients undergoing primary angioplasty for acute myocardial infarction with ST segment elevation MI (STEMI). The trial intends to enroll at least 250 patients with early results expected in 2027 and data read-outs expected through 2028. The adaptive platform approach was selected due to its ability to add subsequent arms to the trial, testing the effectiveness of additional drug candidates delivered through the CorFlow system. Additional countries and research centers are also under evaluation.
Paul Mead, CEO of CorFlow, commented “With the momentum for our expanded clinical program and high interest from KOLs, we are now fortunate to be partnering with many of the top research institutions and physicians in the US and Europe to help bring the technology forward. Between both studies, we will have close to 50 top-tier hospitals engaged, each with a team motivated to see these studies succeed. Interventional cardiology, specifically in the coronary space, is at an exciting time once again with growth drivers and new options for patients. Our technology and clinical studies aim to build on that with a major step forward towards truly complete revascularization, including superior diagnosis and treatment options.”
Alongside the clinical program news, CorFlow has announced that Dr. Rick Kuntz has joined the CorFlow Board of Directors as an Observer and senior scientific advisor. Dr. Kuntz, a renowned interventional cardiologist, was a founder and Chief Scientific Officer of the Harvard Clinical Research Institute and later served at Medtronic as Chief Medical and Scientific Officer, where he oversaw medical affairs, health policy and reimbursement, clinical research activities, and corporate technology for the respected medical device leader. His experience includes guiding clinical programs for numerous technologies through market clearance and subsequent post market research for over 30 years.
CorFlow also announced the appointment of Dr. Pedro Eerdmans as Vice President Clinical. Pedro brings decades of experience from both industry, clinical research organizations, and notified bodies over his career, touching multiple medical fields. Notably, Dr. Eerdmans has helped scale medtech startups for clinical study execution, as well as spent time at larger medical companies such as Biosensors International where he served as VP Medical Affairs overseeing multiple coronary artery stent studies.
Chris O’Connell, the Chairman of the Board of CorFlow, commented, “We are thrilled with the clinical milestones that CorFlow continues to achieve, and equally excited by the added experience of our new team members. I personally had the chance to work with Dr. Kuntz at Medtronic for many years and cannot think of a better addition for CorFlow to help guide our strategic, scientific and regulatory path forward for this breakthrough technology. Our foundation will always be in medical science that puts the patient first, aiming for a new standard of care – which is possible thanks to this strengthened team and the path the company is now on with these landmark studies.”
About CorFlow Therapeutics: Founded and headquartered in Switzerland, with subsidiary operations in both Italy and the United States. The company is venture capital funded with an international VC firm syndicate, most recently with a Series B financing round announced first announced in September 2024. CorFlow aspires to be the leader in diagnostic and therapeutic solutions for restoring healthy microvascular blood flow, starting with cardiac applications for heart attack patients. Working in close partnership with scientists from the University of Bern, ETH Zurich and the University Hospital Zurich, in a collaboration funded by the Swiss Innovation Agency (Innosuisse), CorFlow continues to research applications for the unique patented technology with pharmaceutical options and new use cases.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260430413675/en/
Permalink
https://aetoswire.com/en/news/3004202654677
Contacts
Media and Scientific Contact
CorFlow Therapeutics AG
hello@corflow.ch
SINOVAC Files Annual Report on Form 20-F for the Fiscal Year 2024
BEIJING - Thursday, 30. April 2026
(BUSINESS WIRE) -- Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2024 (the “Annual Report”) with the U.S. Securities and Exchange Commission (“SEC”). An electronic copy of the Annual Report can be accessed on SINOVAC’s investor relations website at https://www.sinovac.com/en-us/Investors and on the SEC’s website at www.sec.gov.
About SINOVAC
Sinovac Biotech Ltd. (SINOVAC) is a China-based global biopharmaceutical company, with a mission of “supply vaccines to eliminate human diseases”, the company specializes in the research, development, manufacturing and commercialization of vaccines and related biological products that protect against human infectious diseases.
The company’s diversified portfolio includes vaccines for influenza, viral hepatitis, varicella, Hand-Foot-Mouth disease (HFMD), poliomyelitis, pneumococcal disease, etc., of which 3 vaccines have been prequalified by WHO, including inactivated hepatitis A vaccine Healive®, Sabin-strain inactivated polio vaccine (sIPV), and varicella vaccine.
SINOVAC has a leading edge in developing vaccines to combat infectious disease outbreaks and was among the first to initiate R&D during major public health emergencies, including SARS, H5N1, H1N1, and COVID-19. The company developed the world’s first inactivated SARS vaccine (Phase I completed), China’s first H5N1 influenza vaccine (Panflu®), the world’s first H1N1 influenza vaccine (Panflu.1®), and CoronaVac®, the most widely used inactivated COVID-19 vaccine globally.
Beyond its marketed portfolio, the company is advancing a robust pipeline that includes combination vaccines, recombinant protein vaccines and next-generation platforms such as mRNA technologies and antibodies.
With a long-standing commitment to innovation and global health, SINOVAC is expanding its global footprint by strengthening partnerships with research institutions, international organizations, and local partners. Through broader market presence, technological cooperation, and localized production, the company aims to accelerate vaccine development and supply, enhance regional access to high-quality products, and better address unmet medical needs while improving preparedness for future pandemics.
For more information, please see the Company’s website at www.sinovac.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260429934070/en/
Permalink
https://www.aetoswire.com/en/news/300420202654686
Contacts
Investor and Media Contact
Sinovac Biotech Ltd.
Email: ir@sinovac.com
Andersen Consulting Strengthens Digital Transformation Capabilities with Weexa
SAN FRANCISCO - Thursday, 30. April 2026 AETOSWire
(BUSINESS WIRE) -- Andersen Consulting enters into a Collaboration Agreement with Weexa, a global provider of digital transformation, B2B integration, and supply chain digitalization solutions.
Headquartered in France, Weexa delivers end-to-end services that help organizations streamline, secure, and scale their digital ecosystems. The firm specializes in B2B data-flow management and digitalization, enabling seamless communication between applications both within and across organizations through technologies such as EDI, APIs, and e-invoicing. Weexa also provides SAP integration and supply chain solutions spanning warehouse and transport management, alongside strategic consulting, project delivery, and third-party application maintenance. Serving organizations across the food, retail, wholesale, logistics, transportation, automotive, healthcare, and media sectors, Weexa supports global businesses in optimizing performance while meeting evolving regulatory and digital-compliance requirements.
“Collaborating with Andersen Consulting allows us to better support clients as they navigate increasingly complex digital ecosystems,” said Jérôme Fleury, CEO of Weexa. “Collaboration is a powerful driver of business growth, and joining the Andersen platform strengthens our ability to build meaningful, long-term relationships. Our expertise in e-invoicing, combined with Andersen’s complementary tax and legal services, enables organizations to ensure compliance through well-integrated communication systems supported by a strong IT foundation.”
“The addition of Weexa further strengthens our ability to deliver integrated, technology-enabled consulting solutions to clients worldwide,” said Mark L. Vorsatz, global chairman and CEO of Andersen. “As organizations face increasing regulatory and operational complexity, the need for connected systems and reliable digital infrastructure continues to grow. Weexa’s service offerings enhance our ability to help clients drive compliance, improve efficiency, and execute digital transformation at scale.”
Andersen Consulting is a global consulting practice providing a comprehensive suite of services spanning corporate strategy, business, technology, and AI transformation, as well as human capital solutions. Andersen Consulting integrates with the multidimensional service model of Andersen Global, delivering world-class consulting, tax, legal, valuation, global mobility, and advisory expertise on a global platform with more than 50,000 professionals worldwide and a presence in over 1,000 locations through its member firms and collaborating firms. Andersen Consulting Holdings LP is a limited partnership and provides consulting solutions through its member firms and collaborating firms around the world.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260430581390/en/
Permalink
https://www.aetoswire.com/en/news/3004202654687
Contacts
mediainquiries@Andersen.com
Thursday, April 30, 2026
ABS Acquires RMC Global to Strengthen Cyber, Risk and Resilience Capabilities
HOUSTON - Thursday, 30. April 2026 AETOSWire
Acquisition to Deliver Stronger, More Integrated Solutions for Clients
(BUSINESS WIRE) -- ABS, through its affiliate ABSG Consulting Inc. (ABS Consulting), has today announced the acquisition of RMC Global (RMC), a leading provider of industrial cybersecurity, risk management and resiliency solutions.
The acquisition strengthens ABS Consulting’s capabilities and market position, bringing together two organizations with complementary expertise, shared values and a common mission. Combining RMC’s capabilities with ABS Consulting’s scale, technical depth and global resources, unlocks more integrated solutions for clients operating in increasingly complex risk environments.
ABS Chairman and CEO John McDonald said: “Clients are facing increasing operational risk, cyber threats, and regulatory pressure. Bringing together the expertise of RMC and ABS Consulting strengthens our ability to deliver even greater value and support for our clients through comprehensive, integrated solutions.”
He highlighted that the acquisition is both a strategic and cultural fit. RMC’s strong culture of critical infrastructure protection and industrial cybersecurity aligns closely with ABS Consulting’s focus on protecting people, assets and critical operations around the world.
He said: “ABS and RMC make a strong fit in mission and culture. Both organizations are focused on work with real-world impact. Both value expertise, practical problem solving, and long-term trust. And both are committed to helping protect critical systems, support resilience, and solve complex challenges in environments where the stakes are high.”
ABS Consulting CEO David Wechsler said: “This acquisition builds on priority areas where we see sustained client demand and long-term growth opportunity. The combination strengthens our ability to support our customers’ evolving operational risk, cyber threats, and regulatory demands, while giving us a broader platform to deliver increasingly innovative solutions.”
RMC President Vince Kuchar said: “What brought our organizations together is a shared culture, mission, and purpose: delivering practical, trusted solutions that protect critical infrastructure and critical missions, enabling resilience in the face of growing risk. By joining ABS with its 164-year mission, we are better positioned to support our clients today and to adapt alongside them in the years ahead.”
More information about ABS Consulting is available here. More information about RMC is available here.
About ABS
ABS, a global leader in classification services, is focused on delivering a safer, cleaner future for the marine and offshore industries. For over 160 years, ABS has been setting standards for safety and excellence and continues to innovate in the fields of clean technology, digitalization and artificial intelligence, providing industry-leading technical advisory services. With a global network of surveyors, engineers, technology specialists and support staff, ABS works with industry leaders including its members and clients around the world to improve safety in operational performance and efficiency with innovative solutions for the complete life cycle of marine and offshore assets.
About RMC Global
RMC is a leading provider of industrial cybersecurity, risk management, and resiliency solutions for critical infrastructure and critical missions. Committed to safeguarding national security and resilience, RMC partners with government and commercial organizations to address evolving threats and vulnerabilities.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260430164690/en/
Permalink
https://www.aetoswire.com/en/news/3004202654690
Contacts
For more information, contact ABS Media Relations: jmire@eagle.org
Subscribe to:
Posts (Atom)